Phio Pharmaceuticals (PHIO) Non Operating Interest Expenses (2024 - 2025)
Phio Pharmaceuticals' (PHIO) quarterly Non Operating Interest Expenses came in at $98000.0 in Q4 2025, up 178.4% quarter-over-quarter from -$125000.0 in Q1 2025.
Powered by 
Analysis
Phio Pharmaceuticals (PHIO) Non Operating Interest Expenses (2024 - 2025) Analysis & Trends
Phio Pharmaceuticals (PHIO) has reported Non Operating Interest Expenses for 2 consecutive years, with $98000.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Non Operating Interest Expenses changed N/A year-over-year to $98000.0; the trailing twelve-month figure through Dec 2025 stood at $98000.0 (changed N/A YoY), and the FY2025 full-year result was $98000.0, changed N/A from the prior year.
- Non Operating Interest Expenses improved to $98000.0 in Q4 2025 per PHIO's latest filing, from -$125000.0 in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at $98000.0 in Q4 2025 and bottomed at -$125000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Phio Pharmaceuticals | 12.08 Mn | 12.08 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 98,000.00 |
| Mar 31, 2025 | -125,000.00 |
| Mar 31, 2024 | -53,000.00 |